Organon & Co. (OGN) to Distribute Quarterly Dividend of $0.02 on September 10th

Organon & Co. (NYSE:OGN) declared a quarterly dividend on Friday, July 31st. Stockholders of record on Friday, August 14th will be paid a dividend of 0.02 per share on Thursday, September 10th. This represents a c) dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Friday, August 14th.

Organon & Co. has a payout ratio of 2.0% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Organon & Co. to earn $3.44 per share next year, which means the company should continue to be able to cover its $0.08 annual dividend with an expected future payout ratio of 2.3%.

Organon & Co. Price Performance

OGN opened at $13.55 on Friday. Organon & Co. has a one year low of $5.69 and a one year high of $13.60. The company has a debt-to-equity ratio of 9.47, a current ratio of 1.97 and a quick ratio of 1.42. The company’s 50 day simple moving average is $13.47 and its 200-day simple moving average is $10.40. The stock has a market capitalization of $3.56 billion, a P/E ratio of 17.60, a price-to-earnings-growth ratio of 1.25 and a beta of 1.54.

Organon & Co. (NYSE:OGN) last issued its quarterly earnings results on Thursday, April 30th. The company reported $0.71 earnings per share for the quarter, missing analysts’ consensus estimates of $0.83 by ($0.12). Organon & Co. had a net margin of 3.99% and a return on equity of 99.95%. The company had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.49 billion. During the same period in the prior year, the business earned $1.02 EPS. The business’s revenue for the quarter was down 3.5% on a year-over-year basis. Sell-side analysts anticipate that Organon & Co. will post 3.23 earnings per share for the current fiscal year.

Insider Buying and Selling at Organon & Co.

In other Organon & Co. news, SVP Lynette Holzbaur acquired 26,448 shares of the business’s stock in a transaction that occurred on Wednesday, May 6th. The shares were acquired at an average cost of $13.35 per share, for a total transaction of $353,080.80. Following the completion of the acquisition, the senior vice president directly owned 52,851 shares of the company’s stock, valued at approximately $705,560.85. This represents a 100.17% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.62% of the stock is currently owned by company insiders.

Institutional Trading of Organon & Co.

Hedge funds have recently modified their holdings of the company. Farther Finance Advisors LLC boosted its stake in Organon & Co. by 87.8% during the 4th quarter. Farther Finance Advisors LLC now owns 4,349 shares of the company’s stock worth $31,000 after acquiring an additional 2,033 shares during the last quarter. Allied Private Wealth LLC bought a new stake in Organon & Co. in the second quarter valued at approximately $33,000. Eurizon Capital SGR S.p.A. acquired a new stake in Organon & Co. in the fourth quarter worth $44,000. Kestra Advisory Services LLC acquired a new stake in Organon & Co. in the fourth quarter worth $47,000. Finally, WNY Asset Management LLC acquired a new stake in Organon & Co. in the first quarter worth $64,000. 77.43% of the stock is currently owned by institutional investors and hedge funds.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.